Niowave and Novartis enter global Actinium-225 supply agreement to advance next-generation cancer therapies

CAR-T Digest - August 2020

11 February 2026: Niowave and Novartis enter global Actinium-225 supply agreement to advance next-generation cancer therapies

Niowave announced a new long-term global supply agreement with Novartis to provide Actinium-225 (Ac-225), strengthening the supply chain for next-generation radioligand therapies designed to precisely target and destroy cancer cells
Under the agreement, Novartis will receive scalable access to Ac-225 to support its expanding portfolio of radioligand therapy programs for difficult-to-treat cancers, while financial terms of the partnership were not disclosed
The collaboration comes at a critical time as demand for alpha-emitting isotopes continues to grow, with Actinium-225 recognized for its ability to deliver highly potent, localized energy capable of destroying tumor cells while limiting damage to surrounding healthy tissue
To meet anticipated demand, Niowave plans to expand its production capacity and begin construction of a new manufacturing facility in Lansing, Michigan, in early 2026, reinforcing its role as a key supplier in the radiopharmaceutical ecosystem
The agreement underscores the increasing importance of securing reliable isotope supply to enable the continued advancement and commercialization of targeted radiotherapies, positioning both companies to accelerate innovation in precision oncology